Trials / Withdrawn
WithdrawnNCT01040585
Cost Effectiveness Of Linezolid In Central America
Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linezolid | Treatment for VAP as indication approved and as physician criterium. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2009-12-29
- Last updated
- 2012-03-02
Source: ClinicalTrials.gov record NCT01040585. Inclusion in this directory is not an endorsement.